The Impact of Erythropoietin on Short- and Long-Term Kidney-Related Outcomes in Neonates of Extremely Low Gestational Age. Results of a Multicenter, Double-Blind, Placebo-Controlled Randomized Clinical Trial

To evaluate whether extremely low gestational age neonates (ELGANs) randomized to erythropoietin have better or worse kidney-related outcomes during hospitalization and at 22-26  months of corrected gestational age (cGA) compared with those randomized to placebo.
Source: The Journal of Pediatrics - Category: Pediatrics Authors: Tags: Original Articles Source Type: research